Today we are exhibiting at the 5th Biennial Biosimilars and Biobetters Congress in London.
It is great to be part of an event that focuses on the key areas of the industry including market access strategies, commercialisation, clinical development, bio-analytics and manufacturing.
Our very own Philip Webber is currently giving a presentation on patenting new biotech products, processes and methods. So far we have learnt where patents fit into the industry and whilst biosimilars need to be clinically similar to the reference product there are still opportunities to patent new processes and formulations.
We are looking forward to hearing more on patenting biobetters, the effect of Brexit and looking out for the new European patent system.
Click on the link below to find out more on patenting medical and biotech inventions: